A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...
The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...
Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...
Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...